Table 1.
Correlations of miR-497 expression with clinicopathologic features of BC patients
| |
miR-497 expression |
|
|
|---|---|---|---|
| Clinicopathologic features | High (n = 74) | Low (n = 54) | P -value |
| Age (years) |
|
|
0.204 |
| ≤50 |
44 |
38 |
|
| >50 |
30 |
16 |
|
| Tumor size (cm) |
|
|
0.777 |
| ≤2.0 |
32 |
22 |
|
| >2.0 |
42 |
32 |
|
| Differentiation grade |
|
|
0.005* |
| G1 + 2 |
46 |
20 |
|
| G3 |
28 |
34 |
|
| Histological type |
|
|
0.078 |
| Ductal |
50 |
44 |
|
| Lobular |
24 |
10 |
|
| ER status |
|
|
0.590 |
| Negative |
34 |
21 |
|
| Positive |
44 |
33 |
|
| PR status |
|
|
0.598 |
| Negative |
18 |
11 |
|
| Positive |
56 |
43 |
|
| HER-2 status |
|
|
0.024* |
| Negative |
49 |
25 |
|
| Positive |
25 |
29 |
|
| Lymph node metastasis |
|
|
0.001* |
| Absent |
47 |
18 |
|
| Present |
27 |
36 |
|
| Clinical stage |
|
|
0.010* |
| I + II |
43 |
19 |
|
| III | 31 | 35 | |
*Statistically significant difference (P < 0.05). ER estrogen receptor;
PR progesterone receptor, HER-2 c-erbB-2.